hotspot -WSS

hotspot

author：entertainment 2025-09-03 07:35:41 - browse：6749

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： A new nitrogen execution bill also undermines medical licensing

WSS

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Medicare wants to send $9 billion to 340B hospitals

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

He's a Nobel laureate. Critics say he was misleading on Covid

explore

hotspot

focus

How one medical school became remarkably diverse

Obesity drugs seen as possible treatment for liver disease MASH

Duchenne breakthrough therapy leaves behind pioneering families

Community Health Systems hospitals under DOJ investigation

Bright Health sells Medicare Advantage business to Molina

In utero gene editing: an explainer

Duchenne breakthrough therapy leaves behind pioneering families

Pandemic and All Hazards Preparedness Act needs lean update

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden targets hefty hospital 'facility fees' that often surprise patients

focus

STAT readers on older presidents, polypills, Medicare, and more

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

STAT readers on older presidents, polypills, Medicare, and more

Pandemic and All Hazards Preparedness Act needs lean update

With competition flaring, obesity drug hits goal in liver disease study

Swim instructor mom warns parents not to buy blue swimsuits for kids

explore

entertainment

explore

hotspot